Immunohistochemical labelling for prostate-specific antigen in breast carcinomas

Area of Science:

• Oncology
• Pathology
• Biomarker Research

Background:

• Prostate-specific antigen (PSA) is primarily associated with prostate cancer.
• PSA has been detected in non-prostatic tissues, including breast carcinomas, using sensitive methods.
• The prognostic significance of PSA in breast cancer remains unclear.

Purpose of the Study:

• To evaluate the prevalence of PSA immunoreactivity in breast carcinoma.
• To determine the prognostic value of PSA expression in breast cancer patients.
• To investigate the association of PSA with clinicopathological features and patient outcomes.

Main Methods:

• Immunohistochemistry was used to detect PSA in 171 breast carcinoma samples.
• PSA staining was correlated with mitotic activity, tumor size, histological grade, and steroid receptors.
• Survival analysis was performed, with subgroup analysis based on menopausal status.

Main Results:

• PSA immunoreactivity was found in 54 (32%) of breast carcinomas.
• PSA positivity did not show prognostic value in the overall patient cohort.
• In premenopausal patients, concomitant absence of PSA and estrogen receptors was linked to a 6.2-fold increased risk of breast cancer death.
• In postmenopausal patients, PSA positivity correlated with progesterone receptor positivity and high differentiation.

Conclusions:

• PSA can be immunohistochemically detected in a significant proportion of breast carcinomas.
• PSA immunoreactivity alone is not a reliable general prognosticator for breast cancer.
• The combined absence of PSA and estrogen receptors is a significant indicator of unfavorable prognosis in premenopausal breast cancer patients.